Lub tsev Iphase Ds8201a

Iphase Ds8201a

Cov lus piav qhia luv luv:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Hu rau tam sim no Ntxiv rau lub tawb nqa khoom

Khoom Qhia Qhia

Khoom Ntawv

Cov Khoom Nrhabrraption discription DS - 8201a, tseem hu ua Trastuzumab derxan (t - DXD), yog tshuaj tiv thaiv antibergate (ADC) tsim rau kev kho mob ntawm HER2 - Cov qog nqaij hlav. Nws ua ke ntawm HER2 - VIM MACOUNDING Monoclonal Antibody (Zoo ib yam li Trastuzumab) Nrog lub zog todoisomerase i inhibitor (deruxan) raws li cytotoxic payload. Cov tshuaj noj cov tshuaj kho mob ncaj qha rau cov qog nqaij hlav cancer qhia txog HER2, txhim kho kev ua kom zoo thaum muaj kev puas tsuaj rau cov hlwb ib txwm muaj.

Qeb:
Tusv loog
Yam khoom tsis tau.:
015200.02
Chav Tsev Loj:
200ul, 2mg / ml
Cov ntaub so ntswg:
N / a
Hom:
N / a
Kev Cia Cov Neeg Cia thiab Tsheb Thauj Mus Los:
Khw ntawm - 70 ° C. Dej khov kom qhuav.

Yav dhau los: IPhase tib neeg Cathepsin B, Hek293

Tom ntej: Iphase Ds8201a

Iphase Ds8201a

Cov lus piav qhia luv luv:

Khoom Qhia Qhia

Khoom Ntawv

Iphase liab (Rhas) PBMC, tshiab

Ipase Luav (New Zealand Dawb) Ntshav, Mixed Cender, H.NWadin Sodium

IPhase tso zis, sib xyaw tub los ntxhais

Iaphas tib neeg cd14 + Monocytes Cells xaiv cov khoom siv zoo, aptamer

Iphase liab ureter nqaij

Iphase liab cov ntaub so ntswg